SCHEMBL112597

SCHEMBL112597

Cc1cncc(NC(=O)c2ccccc2N2CCN(C(=O)Cn3nc(C)cc3C)CC2)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 3/20 0.58
KCNH2 Q12809 1/20 0.58
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 2/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 1/20 0.40
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
PRMT5 O14744 2/20 0.39
WDR77 Q9BQA1 2/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.39
NAMPT P43490 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL114002 0.92 CXCR3 (0.57) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL112666 0.91 CXCR3 (0.56) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL113704 0.91 CXCR3 (0.56) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL110415 0.89 CXCR3 (0.58) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL111889 0.89 CXCR3 (0.67) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL111833 0.88 CXCR3 (0.61) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL111164 0.86 CXCR3 (0.59) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL111619 0.86 CXCR3 (0.58) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR
SCHEMBL112255 0.85 CXCR3 (0.55) CXCR3KCNH2SMN1; SMN2TSHRHSD17B10
SCHEMBL109673 0.85 CXCR3 (0.55) CXCR3KCNH2ALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
EP-2424858-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885KCNH2 1384/4885ALDH1A1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.